Scholars@Duke
construction release_alert
Scholars@Duke will be down for maintenance for approximately one hour starting Tuesday, 11/11 @1pm ET
cancel
Joseph Junyong Park

Joseph Junyong Park

Clinical Faculty in the Department of Medicine
Medicine, Medical Oncology

Selected Publications

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

Journal Article Eur Urol Oncol · August 2025 BACKGROUND AND OBJECTIVE: Up to 5% of patients with metastatic castration-resistant prostate cancer (mCRPC) harbour loss-of-function alterations in mismatch repair genes (dMMR) resulting in microsatellite instability (MSI-H). Data on the efficacy of immune ... Full text Link to item Cite

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.

Journal Article Prostate Cancer Prostatic Dis · June 2025 Featured Publication BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes rema ... Full text Link to item Cite

SPOP mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI).

Conference Journal of Clinical Oncology · June 2025 e17082Background: Inactivating missense mutations in the tumor suppressor gene speckle-type pox virus and zinc finger protein ... Full text Cite

Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).

Conference Journal of Clinical Oncology · June 2025 e17085Background: Inactivating missense mutations in the tumor suppressor gene speckle-type POZ (SPOP) increase the transcrip ... Full text Cite

Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.

Conference Journal of Clinical Oncology · June 2025 e17107Background: In clinical practicea subset of patients treated with androgen deprivation therapy (ADT) plus an ARPI achie ... Full text Cite

Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.

Journal Article Clin Genitourin Cancer · December 2024 BACKGROUND: Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) are associated with immune checkpoint inhibitor (ICI) efficacy. We examined the association between TMB and MSI status with survival in patients with urothelial carcinoma (UC) t ... Full text Link to item Cite

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.

Journal Article JCO Precis Oncol · August 2024 PURPOSE: Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non-BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with PC treated with poly(ADP-ribose)polymera ... Full text Link to item Cite

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.

Journal Article JCO Precis Oncol · April 2024 Featured Publication PURPOSE: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the United States, focused on single versus serial NGS te ... Full text Link to item Cite

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.

Journal Article Clin Cancer Res · March 15, 2024 Featured Publication PURPOSE: HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated with abiraterone or enzalutamide. E ... Full text Link to item Cite

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.

Journal Article JAMA Netw Open · September 5, 2023 IMPORTANCE: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. OBJECTIVE: To compare precision medicine data a ... Full text Link to item Cite

Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).

Conference Journal of Clinical Oncology · June 1, 2023 4574 Background: MTAP loss of function alt in aUC has been associated with poor prognosis. MTAP is an enzyme involved in the adenine salvage pathway and deficiency of the protein leads to susceptibility to antifolate agents, e.g. ... Full text Cite

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · December 2022 BACKGROUND: Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inh ... Full text Link to item Cite

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.

Journal Article BJU Int · November 2022 OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developi ... Full text Link to item Cite

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · October 2022 BACKGROUND: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized th ... Full text Link to item Cite

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · September 2022 PURPOSE: Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to e ... Full text Link to item Cite

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Journal Article Sci Transl Med · June 15, 2022 The majority of JAK2V617F-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens ... Full text Link to item Cite

Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · June 1, 2022 5013 Background: Black men have been underrepresented in large-scale molecular prostate cancer (PC) surveys, despite having higher PC incidence and mortality. Since molecular profiling to guide the use of targeted agents is incre ... Full text Cite

Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.

Journal Article Clin Genitourin Cancer · April 2022 BACKGROUND: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without ... Full text Link to item Cite

Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).

Conference Journal of Clinical Oncology · February 20, 2022 138 Background: AR alterations such as ligand binding domain mutations and amplification evolve under the selective pressure of testosterone suppression and AR targeted agents (ARTA) such as abiraterone or enzalutamide, but their ... Full text Cite

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Conference Journal of Clinical Oncology · February 20, 2022 129 Background: Pathogenic HRR gene mutations may confer sensitivity to PARP inhibitors (PARPi) and/or platinum chemotherapy (chemo). While pts harboring mutations in BRCA1/2 appear to benefit from these DNA damaging therapeutics ... Full text Cite

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.

Journal Article BJU Int · August 2021 OBJECTIVES: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). PATIENTS AND METHODS: We performed a ... Full text Link to item Cite

A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

Journal Article Eur Urol Oncol · June 2021 BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain ... Full text Link to item Cite

Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.

Conference Journal of Clinical Oncology · May 20, 2021 e16526 Background: ICIs have altered the therapeutic landscape in pts with aUC and new biomarkers are needed to better predict response and outcomes with ICIs. It is unclear whether demographics, such as race, age, sex and histor ... Full text Cite

Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.

Conference Journal of Clinical Oncology · May 20, 2021 4568 Background: Advanced sRCC is an aggressive disease with limited responsiveness to chemotherapy and VEGF-targeted therapies. Subgroup analyses from randomized trials showed improved outcomes with ICI, though sample sizes were ... Full text Cite

Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.

Conference Journal of Clinical Oncology · February 20, 2021 406 Background: Despite anatomical and biological differences, upper and lower tract UC (UTUC; LTUC) are usually managed similarly. Modern era clinical trial data comparing their outcomes with ICI are conflicting. We hypothesized ... Full text Cite

Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.

Conference Journal of Clinical Oncology · February 20, 2021 328 Background: Anti-PD1/PDL1 immune checkpoint inhibition (CPI) is active in advanced clear cell RCC, but not all patients benefit. Preclinical studies with the combination of hypomethylating agents and CPI resulted in reversal ... Full text Cite

Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).

Conference Journal of Clinical Oncology · February 20, 2021 444 Background: It is unclear whether prior RS of primary tumor is associated with response and outcomes with ICI in aUC. We hypothesized that such response and outcomes would not differ based on prior RS. Methods: We performed a ... Full text Cite

Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms

Conference The Journal of Immunology · May 1, 2020 AbstractThe majority of JAK2WT myeloproliferative neoplasms (MPN) have disease-initiating frameshift mutations in calreticulin (CALR) resulting in a common novel C-terminal mutant fragment (CALRMUT), represe ... Full text Cite

Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience.

Journal Article Cancer Treat Res Commun · 2020 INTRODUCTION: Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognosis. We ... Full text Link to item Cite

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.

Journal Article Acta Oncol · December 2017 BACKGROUND: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for unresectable pancreatic cancer, and is postulated to be more effective and less toxic than conventionally fractionated intensity modulated radiation therapy (IMRT). ... Full text Link to item Cite

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.

Conference Journal of Clinical Oncology · February 1, 2017 353 Background: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for unresectable pancreatic cancer, and may be more effective and less toxic than intensity modulated radiation therapy (IMRT). Methods: W ... Full text Cite

Expression and alternative splicing of classical and nonclassical MHCI genes in the hippocampus and neuromuscular junction.

Journal Article Mol Cell Neurosci · April 2016 The major histocompatibility complex class I (MHCI) is a large gene family, with over 20 members in mouse. Some MHCIs are well-known for their critical roles in the immune response. Studies in mice which lack stable cell-surface expression of many MHCI pro ... Full text Link to item Cite

MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling.

Journal Article J Neurosci · August 27, 2014 Proteins of the major histocompatibility complex class I (MHCI) negatively regulate synapse density in the developing vertebrate brain (Glynn et al., 2011; Elmer et al., 2013; Lee et al., 2014), but the underlying mechanisms remain largely unknown. Here we ... Full text Link to item Cite

Interleukin-6 expands homeostatic space for peripheral T cells.

Journal Article Cytokine · November 2013 T cell homeostasis and survival is dependent on interleukin-7 (IL-7). Immune activation, however, downregulates IL-7 receptor expression on T cells so that T cell survival during activation must be maintained independently of IL-7. The pro-inflammatory cyt ... Full text Link to item Cite